367 related articles for article (PubMed ID: 29981151)
1. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.
Schlessinger A; Welch MA; van Vlijmen H; Korzekwa K; Swaan PW; Matsson P
Clin Pharmacol Ther; 2018 Nov; 104(5):818-835. PubMed ID: 29981151
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Reduce Solute Carrier-Mediated Toxicity.
Hu S; Sprowl JA
Clin Pharmacol Ther; 2018 Nov; 104(5):799-802. PubMed ID: 30028006
[TBL] [Abstract][Full Text] [Related]
3. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.
Evers R; Piquette-Miller M; Polli JW; Russel FGM; Sprowl JA; Tohyama K; Ware JA; de Wildt SN; Xie W; Brouwer KLR;
Clin Pharmacol Ther; 2018 Nov; 104(5):900-915. PubMed ID: 29756222
[TBL] [Abstract][Full Text] [Related]
4. Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW; Brackman DJ; Ennis EA; Sugiyama Y; Kamdem LK; Blanchard R; Galetin A; Zhang L; Giacomini KM
Clin Pharmacol Ther; 2018 Nov; 104(5):803-817. PubMed ID: 29679469
[TBL] [Abstract][Full Text] [Related]
5. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.
Zamek-Gliszczynski MJ; Taub ME; Chothe PP; Chu X; Giacomini KM; Kim RB; Ray AS; Stocker SL; Unadkat JD; Wittwer MB; Xia C; Yee SW; Zhang L; Zhang Y;
Clin Pharmacol Ther; 2018 Nov; 104(5):890-899. PubMed ID: 30091177
[TBL] [Abstract][Full Text] [Related]
6. The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development.
Giacomini KM; Galetin A; Huang SM
Clin Pharmacol Ther; 2018 Nov; 104(5):766-771. PubMed ID: 30137696
[No Abstract] [Full Text] [Related]
7. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.
Chu X; Liao M; Shen H; Yoshida K; Zur AA; Arya V; Galetin A; Giacomini KM; Hanna I; Kusuhara H; Lai Y; Rodrigues D; Sugiyama Y; Zamek-Gliszczynski MJ; Zhang L;
Clin Pharmacol Ther; 2018 Nov; 104(5):836-864. PubMed ID: 30347454
[TBL] [Abstract][Full Text] [Related]
8. Transporters and drug-drug interactions: important determinants of drug disposition and effects.
König J; Müller F; Fromm MF
Pharmacol Rev; 2013 Jul; 65(3):944-66. PubMed ID: 23686349
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
Momper JD; Tsunoda SM; Ma JD
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
[TBL] [Abstract][Full Text] [Related]
10. Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity.
Koo SH; Lo YL; Yee JY; Lee EJ
Expert Opin Drug Metab Toxicol; 2015; 11(12):1821-37. PubMed ID: 26489003
[TBL] [Abstract][Full Text] [Related]
11. Potentiating SLC transporter activity: Emerging drug discovery opportunities.
Rives ML; Javitch JA; Wickenden AD
Biochem Pharmacol; 2017 Jul; 135():1-11. PubMed ID: 28214518
[TBL] [Abstract][Full Text] [Related]
12. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.
Dantzig AH; de Alwis DP; Burgess M
Adv Drug Deliv Rev; 2003 Jan; 55(1):133-50. PubMed ID: 12535578
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
14. Effects of Drug Transporters on Pharmacological Responses and Safety.
Liu CX; Yi XL; Fan HR; Wu WD; Zhang X; Xiao XF; He X
Curr Drug Metab; 2015; 16(9):732-52. PubMed ID: 26630905
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence-based methods for studying activity and drug-drug interactions of hepatic solute carrier and ATP binding cassette proteins involved in ADME-Tox.
Özvegy-Laczka C; Ungvári O; Bakos É
Biochem Pharmacol; 2023 Mar; 209():115448. PubMed ID: 36758706
[TBL] [Abstract][Full Text] [Related]
16. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
Langer O
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Toxicokinetics Roles of Membrane Transporters at Kidney Level.
Veiga-Matos J; Remião F; Motales A
J Pharm Pharm Sci; 2020; 23():333-356. PubMed ID: 32997956
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
19. Molecular modeling and ligand docking for solute carrier (SLC) transporters.
Schlessinger A; Khuri N; Giacomini KM; Sali A
Curr Top Med Chem; 2013; 13(7):843-56. PubMed ID: 23578028
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
